Crosato Martino, Steinborn Wolfram, Anker Stefan D
Imperial College, National Heart & Lung Institute, Department of Clinical Cardiology, London, UK.
Heart Fail Monit. 2003;4(1):2-6.
Chronic heart failure (CHF) is a leading cause of morbidity and mortality. Although a precise definition for a cut-off value of hemoglobin level for anemia is still lacking, it has recently been found to be a common complication in CHF, occurring in 10-20% of patients. There are several possible pathogenetic mechanisms for anemia in CHF, and a precise underlying cause is found in only a minority of patients. In CHF, more than 50% of anemia cases are considered to be 'anemia in chronic illness'. In CHF patients, low hemoglobin values directly relate to poor peak oxygen consumption, disabling symptoms, and impaired survival. Recent pilot studies showed that correction of anemia with erythropoietin and iron may lead to improvement in symptoms and exercise capacity. These issues need to be tested in larger, double-blind, randomized, placebo-controlled trials before anemia treatment becomes routine in patients with CHF.
慢性心力衰竭（CHF）是发病和死亡的主要原因。尽管目前仍缺乏关于贫血血红蛋白水平临界值的精确界定，但最近发现贫血是CHF的常见并发症，在10%-20%的患者中出现。CHF患者贫血有多种可能的发病机制，只有少数患者能找到确切的潜在病因。在CHF中，超过50%的贫血病例被认为是“慢性病贫血”。在CHF患者中，低血红蛋白值直接与峰值耗氧量低、致残症状和生存受损相关。最近的初步研究表明，使用促红细胞生成素和铁剂纠正贫血可能会改善症状和运动能力。在贫血治疗成为CHF患者的常规治疗方法之前，这些问题需要在更大规模的双盲、随机、安慰剂对照试验中进行验证。
